

%201.webp)


%201.webp)




LSPedia 的全球序列化系列
序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
.avif)
欢迎来到 LspEdia,在这里,创新与奉献精神相结合。
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。



%201.webp)


%201.webp)




序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
.avif)
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。

Brazil previously planned to implement a national pharmaceutical serialization system known as the National Drug Control System (SNCM) under the authority of the Brazilian Health Regulatory Agency (ANVISA). The program aimed to establish full traceability of medicines across the supply chain using serialization and electronic reporting.
However, the national serialization mandate was revoked before full nationwide implementation. The Brazilian government formally withdrew the SNCM traceability mandate, and there is currently no active national requirement for pharmaceutical serialization or serial level reporting in Brazil.
Pharmaceutical traceability in Brazil therefore operates primarily through batch level identification, supply chain documentation, and regulatory oversight managed by ANVISA.
Brazil does not currently require serialized DataMatrix barcodes for pharmaceutical products.
Medicines marketed in Brazil must include standard identification information on the packaging, including:
Barcodes may be used for internal supply chain or commercial purposes, typically encoding a GTIN, but serialization of individual packs is not mandated.
Human readable packaging information must match the information encoded in any barcode used.
2009 – Brazilian government introduces legislation aimed at strengthening pharmaceutical supply chain security.
2013 – Law No. 11.903 establishes the National Drug Control System (SNCM) with the goal of implementing serialization and traceability.
2016 – ANVISA publishes regulations defining serialization and reporting requirements for the SNCM system.
2018 to 2021 – Pilot implementations and industry preparations take place.
2022 – The Brazilian government withdraws the national serialization mandate, effectively suspending the SNCM implementation.
There is currently no mandatory national serialization program in force.
Traceability is maintained at the batch level rather than individual pack serialization.
Brazil does not operate a national pharmaceutical serialization repository or centralized track and trace reporting system.
The previously proposed SNCM platform is no longer implemented, and supply chain participants are not required to report serialization events to a national hub.
Regulatory oversight is maintained through:
ANVISA relies on these records during inspections and investigations.
There is no national regulatory requirement for aggregation or packaging hierarchy reporting in Brazil.
Manufacturers and distributors may use logistics identifiers such as SSCC for internal warehouse and transportation operations.
Aggregation structures may be implemented voluntarily for operational efficiency but are not mandated by regulation.
We invite you to learn more about how LSPedia can support your compliance and supply chain needs. For more information about our solutions, partnership opportunities, or to speak with one of our experts.